The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To explore the effects of empagliflozin on the incidence of obstructive sleep apnea (OSA) and its effects on metabolic, cardiovascular (CV), and renal outcomes among participants with or without OSA in the EMPA-REG OUTCOME trial. RESEARCH DESIGN AND METHODS: Participants with diabetes and CV disease were randomized to empagliflozin (10 and 25 mg) or placebo daily in addition to standard of care. OSA was assessed by investigator report using Medical Dictionary for Regulatory Activities version 18.0, and CV outcomes were independently adjudicated. Analyses were performed using multivariable-adjusted Cox regression models. RESULTS: OSA was reported in 391 of 7,020 (5.6%) participants at baseline. Those with OSA were more likely to be male (83% vs. 71%) and to have moderate to severe obesity (BMI ≥35 kg/m2; 55% vs. 18%). Over a median of 3.1 years, empagliflozin had similar placebo-adjusted reductions in HbA1c, waist circumference, and systolic blood pressure, regardless of OSA status, but a larger effect on weight (adjusted mean ± SE difference at week 52: OSA vs. no OSA −2.9 ± 0.5 vs. −1.9 ± 0.1 kg). Incidence of 3-point major adverse CV events, CV death, heart failure hospitalization, and incident or worsening nephropathy in the placebo group was 1.2- to 2.0-fold higher for those with baseline OSA compared with those without. Empagliflozin significantly reduced the risk for outcomes regardless of OSA status (P-interaction all >0.05). Fifty patients reported a new diagnosis of OSA through 7 days after medication discontinuation, and this occurred less often with empagliflozin treatment (hazard ratio 0.48 [95% CI 0.27, 0.83]). CONCLUSIONS: In EMPA-REG OUTCOME, participants with OSA had greater comorbidity and higher frequency of CV and renal events. Empagliflozin had favorable effects on risk factors and CV and renal outcomes regardless of preexisting OSA and may also reduce the risk for new-onset OSA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“SGLT2i have been shown to reduce incident obstructive sleep apnea in two SGLT2i CVOTs based on adverse event reporting (304,305).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationHealth effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Increased Prevalence of Sleep-Disordered Breathing in Adults
Peppard, P. E., Young, T., Barnet, J. H., Palta, M., Hagen, E. W., & Hla, K. M. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws342 · Cited by 4,618 · cited 1×
“, at 50–70 years, 9% in women and 17% in men) (2).”
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationObstructive Sleep Apnea as a Risk Factor for Stroke and Death
Yaggi, H. K., Concato, J., Kernan, W. N., Lichtman, J. H., Brass, L. M., & Mohsenin, V. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043104 · Cited by 3,004 · cited 1×
“OSA and type 2 diabetes frequently occur together, and both are associated with adverse metabolic consequences that increase the risk for cardiovascular disease (CVD) (4), including stroke, myocardial infarction, hospitalization for heart failure (HHF), cardiovascular (CV) death, and all-cause mortality (5,6), as well…”
BackgroundSelf-citationThe epidemiology of adult obstructive sleep apnea
Punjabi, N. M. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200709-155mg · Cited by 2,361
Drager, L. F., Togeiro, S. M., Polotsky, V. Y., & Lorenzi-Filho, G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.045 · Cited by 886
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740 · cited 1×
“on CV deaths (19) (Supplementary Appendix,”
Self-citationObstructive Sleep Apnea and Diabetes
Reutrakul, S., & Mokhlesi, B. (2017) · Chest · doi:10.1016/j.chest.2017.05.009 · Cited by 667 · cited 1×
“Furthermore, OSA may worsen glucose tolerance, impair diabetes management, and lead to poor glycemic control (8).”
BackgroundObstructive Sleep Apnea in Adults
Veasey, S. C., & Rosen, I. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmcp1816152 · Cited by 615
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Ahmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Gliflozins in the Management of Cardiovascular Disease
Braunwald, E. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2115011 · Cited by 266
Obesity and Obstructive Sleep Apnea
Bonsignore, M. R. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_558 · Cited by 126
Metadata
- Authors
- Neeland, I. J., Eliasson, B., Kasai, T., Marx, N., Zinman, B., Inzucchi, S. E., Wanner, C., Zwiener, I., Wojeck, B. S., Yaggi, H. K., & Johansen, O. E.
- Affiliations
- Case Western Reserve University (US)
- Department of Medicine, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
- Juntendo University (JP)
- Universitätsklinikum Aachen (DE)
- Mount Sinai Hospital (CA)
- Yale University (US)
- Universitätsklinikum Würzburg (DE)
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim (Norway) (NO)
- Corresponding author
- Neeland, Ian J.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-10-01
- Volume
- 43
- Issue
- 12
- Pages
- 3007-3015
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7770278
- OpenAlex
- W3091412683
- Cited by
- 93
- References
- 38
- Citations by year
- 2026: 10 · 2025: 19 · 2024: 19 · 2023: 13 · 2022: 24 · 2021: 8
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- National Institute of Diabetes and Digestive and Kidney Diseases (K23-DK-106520)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, obstructive sleep apnea, EMPA-REG OUTCOME trial, type 2 diabetes, cardiovascular outcomes, renal outcomes, heart failure hospitalization, kidney disease, obesity, SGLT2 inhibitors, major adverse cardiovascular events
- MeSH terms
- Aged, Benzhydryl Compounds, Cardiovascular Diseases, Cardiovascular System, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glucosides, Humans, Kidney Diseases, Male, Middle Aged, Risk Factors, Sleep, Comorbidity, Incidence, Prevalence, Treatment Outcome, Sleep Apnea, Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.